Stay up to date with the latest developments in high-risk LBCL and R/R DLBCL with content from key international congresses, video discussions and breaking news stories.
Latest content
Rapid manufacturing: Speeding up access to effective CAR-T cell therapies
30 July 2025
CAR-T-cell therapy has revolutionized the treatment landscape for lymphoma, yet access to this treatment remains constrained by complex and lengthy manufacturing processes.
Clinical commentary
30 July 2025
CAR-T-cell therapy has revolutionized the treatment landscape for lymphoma, yet access to this treatment remains constrained by complex and lengthy manufacturing processes.
EHA 2025
Latest findings from the ATLANTA-1 trial of GLPG5101
19 June 2025
Dr Pim Mutsaers discusses the latest findings from the ATALANTA-1 trial of GLPG5101, which uses a decentralized platform, in patients with R/R NHL.
Video interview
EHA 2025
19 June 2025
Dr Pim Mutsaers discusses the latest findings from the ATALANTA-1 trial of GLPG5101, which uses a decentralized platform, in patients with R/R NHL.
EHA 2025
CAR-T cell therapy in LBCL and immunotherapy highlights
18 June 2025
Dr Eddie Cliff sets the scene for CAR-T cell therapy in LBCL and gives some of his immunotherapy highlights from the EHA2025 Congress in Milan, Italy.
Video interview
EHA 2025
18 June 2025
Dr Eddie Cliff sets the scene for CAR-T cell therapy in LBCL and gives some of his immunotherapy highlights from the EHA2025 Congress in Milan, Italy.
EHA 2025
Bi-specific CAR-T cell therapy shows promise for R/R LBCL
17 June 2025
Early support for further development of dual CD19 and CD20 targeting in CAR-T cell treatment for patients with relapsed/refractory large-B cell lymphoma.
News story
EHA 2025
17 June 2025
Early support for further development of dual CD19 and CD20 targeting in CAR-T cell treatment for patients with relapsed/refractory large-B cell lymphoma.
EHA 2025
IL-15 polymer conjugate enhances liso-cel response in R/R LBCL
17 June 2025
Promising CAR-T cell expansion and persistence with the addition of NKTR-255 to lisocabtagene maraleucel in patients with relapsed/refractory large B-cell lymphoma.
News story
EHA 2025
17 June 2025
Promising CAR-T cell expansion and persistence with the addition of NKTR-255 to lisocabtagene maraleucel in patients with relapsed/refractory large B-cell lymphoma.
EHA 2025
Fast production, low high-grade toxicity with CAR-T cell therapy in R/R NHL
17 June 2025
ATALANTA-1 study shows a manageable safety profile for the CAR T-cell therapy GLPG5101 for patients with relapsed/refractory non-Hodgkin lymphoma
News story
EHA 2025
17 June 2025
ATALANTA-1 study shows a manageable safety profile for the CAR T-cell therapy GLPG5101 for patients with relapsed/refractory non-Hodgkin lymphoma
